

Special Issue

Vectored Vaccines

Message from the Guest Editors

Vectored vaccines reached important milestones in term of safety and efficacy over the last decade. With the FDA approval in December 2019 of Erbevo, a recombinant Vesicular Stomatitis Virus-Vectored vaccine against Zaire Ebola Virus infection and China FDA approval in October 2017 of an Adenovirus-vectored Ebola vaccine established the regulatory baselines of two important recombinant vaccination platforms. This special issue will focus on bringing forward the most advanced research and development work on vectored vaccines from antigen design, immunogenicity, protection, manufacturing and delivery. Articles bringing novel perspectives on this broad topic are also welcome including recombinant viral vectors developed as immunotherapeutics or therapeutic vaccines.

Guest Editors

Prof. Dr. Amine A. Kamen

Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada

Prof. Dr. Olivier Henry

Department of Chemical Engineering, Polytechnique Montréal, Montréal, QC, Canada

Deadline for manuscript submissions

closed (31 March 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/55823

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).